Alnylam Pharmaceuticals filings document the regulatory record for a Nasdaq-listed biopharmaceutical company built around RNA interference therapeutics. Recent Form 8-K reports furnish operating results and financial condition updates tied to product revenues from AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, while other current reports disclose strategy updates, pipeline goals and clinical-program context.
The filing record also covers governance and capital structure matters, including the definitive proxy statement, executive compensation and equity-award disclosures, common stock registered on Nasdaq, a revolving credit facility and convertible senior note offering materials. These disclosures describe board oversight, compensation plans, financing arrangements, material corporate events and the formal exhibits supporting Alnylam's public-company reporting.
Alnylam Pharmaceuticals, Inc. expanded its Board of Directors from ten to eleven members, appointing Benjamin F. Cravatt, Ph.D. as a Class III director effective June 1, 2026, with a term running until the 2028 annual stockholder meeting. He will also join the Board’s Science and Technology Committee.
As a non-employee director, Dr. Cravatt will receive a $75,000 annual cash retainer and an initial stock option grant with a $600,000 grant date fair value, vesting in three equal annual installments, with an exercise price set at the common stock closing price on the grant date.
The filing also reports results of the 2026 annual meeting. As of the March 25, 2026 record date, 133,427,910 common shares were outstanding. Stockholders re-elected three Class I directors, approved on an advisory basis the compensation of named executive officers, and ratified the appointment of PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026.
ALNYLAM PHARMACEUTICALS, INC. director Charles Elliott Sigal reported new equity awards and updated holdings. He received 671 restricted stock units (RSUs), each representing a contingent right to one share of common stock, granted at no cash cost. These RSUs vest in full on the first anniversary of the grant date or upon an earlier qualifying retirement or resignation that occurs no more than 90 days before that anniversary. He was also granted a stock option for 1,441 shares of common stock at an exercise price of $298.48 per share, with the same vesting schedule and an expiration date in 2036. After these awards, he holds 1,446 common shares directly and 2,000 shares indirectly through Sigal Family Investments, LLC.
ALNYLAM PHARMACEUTICALS, INC. director Amy W. Schulman reported equity compensation awards rather than open-market trades. On May 20, 2026, she received 838 restricted stock units (RSUs), each representing one share of common stock, increasing her direct common stock holdings to 24,049 shares after the grant.
She was also granted stock options on 1,802 shares of common stock with a $298.48 exercise price, expiring on May 20, 2036. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or a qualifying retirement or resignation that occurs no more than 90 days before that anniversary.
Alnylam Pharmaceuticals director Colleen F. Reitan received new equity awards as part of her compensation. She was granted 671 restricted stock units, each representing one share of common stock, increasing her direct holdings to 1,446 common shares after the award.
She also received a stock option covering 1,441 common shares at an exercise price of $298.48 per share. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or her earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary.
Alnylam Pharmaceuticals director David E. I. Pyott reported new equity awards and updated holdings. He received 671 restricted stock units, each representing one share of common stock, increasing his direct holdings to 1,582 shares.
He was also granted stock options for 1,441 shares at an exercise price of $298.48 per share, vesting in full on the earlier of one year from grant or certain retirement or resignation conditions. Separately, a trust for which he is trustee holds 27,900 Alnylam shares, reported as indirect ownership.
ALNYLAM PHARMACEUTICALS, INC. director Peter N. Kellogg reported equity awards as part of his compensation. He received 671 restricted stock units, each representing one share of common stock, and 1,441 stock options with an exercise price of $298.48 per share.
The RSUs and options will each vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or his earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary. After the RSU grant, he directly holds 1,446 common shares and 1,441 stock options.
ALNYLAM PHARMACEUTICALS, INC. director Margaret A. Hamburg reported equity awards consisting of common stock and stock options. She received 671 shares of common stock in the form of restricted stock units (RSUs) that each convert into one share when they vest. The RSUs will vest in full on the earlier of the first anniversary of the May 20, 2026 grant or an earlier retirement or resignation that occurs no more than 90 days before that date. She was also granted stock options for 1,441 shares of common stock at an exercise price of $298.4800 per share, with the same vesting schedule. After these awards, her directly held common stock position reported in this filing is 1,582 shares, and she holds options for 1,441 underlying shares.
ALNYLAM PHARMACEUTICALS, INC. director Olivier Brandicourt reported compensation-related equity awards, not open-market trades. He received 671 shares of common stock in the form of restricted stock units granted at no cash cost.
Brandicourt was also granted stock options for 1,441 shares of common stock at an exercise price of $298.48 per share. Both the RSUs and the options vest in full on the earlier of the first anniversary of the May 20, 2026 grant date or his earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary. Following these awards, he directly holds 1,446 common shares and 1,441 stock options.
ALNYLAM PHARMACEUTICALS, INC. director Dennis A. Ausiello reported equity awards and updated holdings. He received a grant of 671 restricted stock units, each representing one future share of common stock, which will vest in full on the first anniversary of the grant date or upon certain earlier retirement or resignation conditions. He was also granted stock options on 1,441 shares at an exercise price of $298.48 per share, with the option vesting on the same schedule. Following these awards, he holds 1,582 shares of common stock directly, 1,441 stock options directly, and 3,500 shares of common stock indirectly through a trust for which his spouse is trustee.